España
Acceder
  1. Inicio
  2. Perfil de Knikord
  3. Contenidos recomendados por Knikord

Contenidos recomendados por Knikord

Knikord 11/03/23 15:58
Ha respondido al tema Novavax (NVAX): Un Nuevo Comienzo
GP Vaccination Market to Witness Massive Growth by Novavax, BioNTech, Modernahttps://www.newstrail.com/gp-vaccination-market-to-witness-massive-growth-by-novavax-biontech-moderna/Porca miseria!..
Ir a respuesta
Knikord 18/01/23 14:17
Ha respondido al tema Novavax (NVAX): Un Nuevo Comienzo
 Novavax Nuvaxovid COVID-19 Vaccine Approved in South Korea as an Adult BoosterJan 18, 2023GAITHERSBURG, Md., Jan. 18, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that partner SK bioscience has received expanded manufacturing and marketing approval from the Korean Ministry of Food and Drug Safety (KMFDS) for Nuvaxovid™ (NVX-CoV2373) for use as a booster for active immunization to prevent COVID-19 in adults aged 18 and older. Prior to the approval, in September 2022, the Korean Centers for Disease Control and Prevention set out recommendations that advised that Nuvaxovid could be used as a booster in adults aged 18 and older."We are pleased to collaborate with SK bioscience to offer our protein-based vaccine, Nuvaxovid, for use as a booster in adults regardless of previous vaccine history," said Stanley C. Erck, President and Chief Executive Officer, Novavax. "This is an important step in ensuring broad access to diversified vaccine options." https://ir.novavax.com/2023-01-18-Novavax-Nuvaxovid-COVID-19-Vaccine-Approved-in-South-Korea-as-an-Adult-Booster
Ir a respuesta
Knikord 14/01/23 07:22
Ha respondido al tema Novavax (NVAX): Un Nuevo Comienzo
In January 2020, at the beginning of the pandemic, the company was "down to 100 people, down to $100M market cap, and down to enough money to get through May that year," Erck said.Today, the company boasts a commercial product that is approved in 47 countries in the past year, roughly 2,000 employees, over $1 billion in the bank, and ened 2022 with a record $2 billion revenue from year one of sales.https://nz.finance.yahoo.com/news/outgoing-novavax-ceo-the-government-has-to-get-out-of-the-way-194311386.htmlY con la misma cotización que entonces?. Hay algo que no cuadra…
Ir a respuesta
Knikord 16/12/22 22:06
Ha respondido al tema Novavax (NVAX): Un Nuevo Comienzo
!!!Que espectáculo!!!En dos días, se han intercambiado la práctica totalidad de los títulos de la compañía, algo más. Supongo que es una parte de ellos en modo noria entre los grandes manipuladores del mercado. Esto deja claro, por si no lo estaba, que el business, el gran business está en los derivados. El subyacente, es secundario, es el mamporrero y puede esperar. Yo derivados, ni olerlos, me provocan náusea.Pues nada, aprovechamos la coyuntura en la medida de lo posible y nos armaremos de paciencia.
Ir a respuesta
Knikord 12/12/22 21:42
Ha respondido al tema Novavax (NVAX): Un Nuevo Comienzo
Novavax is also evaluating a COVID-19-influenza combination (CIC) vaccine candidate in a phase I/II study. The CIC vaccine combines NVX-CoV2373, its authorized protein-based COVID vaccine, and its investigational influenza vaccine in a single formulation. In October, Novavax announced top-line data from this study which demonstrated the CIC vaccine was feasible and immunogenic. The immune responses were comparable to the standalone influenza vaccine candidate and standalone NVX-CoV2373 formulations. Novavax expects to begin a confirmatory phase II study evaluating this vaccine by this year’s end.
Ir a respuesta
Knikord 04/11/22 14:36
Ha respondido al tema Novavax (NVAX): Un Nuevo Comienzo
Así que, en pocas palabras, Novavax tiene una vacuna segura que se adapta a las nuevas variantes, según el Dr. Glenn, tiene evidencia para prevenir la transmisión y es muy duradera.La vacuna de ARNm debilita su sistema inmunológico, el agotamiento de las células T, disminuye rápidamente, causa efectos secundarios intensos, prolonga el aclaramiento del virus, entra en la circulación sistémica y, además de eso, confunde al sistema inmunitario mediante la impresión. La última parte es la más aterradora de todas para mí. Significa que cualquier futura vacuna específica de ARNm que presenten, el cuerpo solo puede escupir los viejos anticuerpos.(Copiado de Yahoo Finance)
Ir a respuesta